Concepts (63)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 4 | 2024 | 45 | 2.700 |
Why?
|
| Furans | 3 | 2026 | 9 | 1.680 |
Why?
|
| Lignans | 3 | 2026 | 9 | 1.680 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 72 | 0.850 |
Why?
|
| Exosomes | 1 | 2022 | 7 | 0.720 |
Why?
|
| Neoplasms | 1 | 2022 | 92 | 0.660 |
Why?
|
| Receptors, CCR2 | 1 | 2020 | 4 | 0.650 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 12 | 0.650 |
Why?
|
| Tumor Burden | 1 | 2020 | 19 | 0.630 |
Why?
|
| Adipose Tissue | 1 | 2020 | 69 | 0.610 |
Why?
|
| Inflammation | 1 | 2020 | 143 | 0.590 |
Why?
|
| Animals | 6 | 2026 | 1875 | 0.570 |
Why?
|
| Obesity | 1 | 2020 | 226 | 0.530 |
Why?
|
| Male | 4 | 2024 | 3671 | 0.400 |
Why?
|
| Mice | 4 | 2026 | 746 | 0.390 |
Why?
|
| Prostate | 2 | 2024 | 15 | 0.370 |
Why?
|
| Humans | 6 | 2026 | 6794 | 0.330 |
Why?
|
| Breast Neoplasms | 2 | 2026 | 170 | 0.330 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2026 | 38 | 0.250 |
Why?
|
| Cell Line, Tumor | 3 | 2026 | 156 | 0.240 |
Why?
|
| Apoptosis | 2 | 2026 | 179 | 0.220 |
Why?
|
| Tensins | 1 | 2024 | 2 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2024 | 6 | 0.210 |
Why?
|
| Chemoprevention | 1 | 2024 | 9 | 0.210 |
Why?
|
| Tea | 1 | 2024 | 6 | 0.210 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2024 | 19 | 0.210 |
Why?
|
| Quercetin | 1 | 2024 | 9 | 0.210 |
Why?
|
| Cell Proliferation | 2 | 2026 | 143 | 0.200 |
Why?
|
| Mice, Knockout | 1 | 2024 | 150 | 0.200 |
Why?
|
| Phytochemicals | 1 | 2022 | 3 | 0.190 |
Why?
|
| Hormones | 1 | 2022 | 11 | 0.190 |
Why?
|
| Neovascularization, Pathologic | 1 | 2022 | 23 | 0.190 |
Why?
|
| Ligands | 1 | 2022 | 17 | 0.180 |
Why?
|
| Disease Models, Animal | 2 | 2020 | 231 | 0.180 |
Why?
|
| Models, Biological | 1 | 2022 | 64 | 0.180 |
Why?
|
| MicroRNAs | 1 | 2022 | 54 | 0.170 |
Why?
|
| Adipokines | 1 | 2020 | 3 | 0.160 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 11 | 0.160 |
Why?
|
| Receptors, Androgen | 1 | 2020 | 20 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2020 | 54 | 0.160 |
Why?
|
| Adipocytes | 1 | 2020 | 31 | 0.160 |
Why?
|
| Transcription Factors | 1 | 2020 | 53 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 155 | 0.150 |
Why?
|
| Cytokines | 1 | 2020 | 80 | 0.150 |
Why?
|
| Diet, High-Fat | 1 | 2020 | 59 | 0.150 |
Why?
|
| Protein Phosphatase 2C | 1 | 2018 | 4 | 0.140 |
Why?
|
| Curcumin | 1 | 2018 | 8 | 0.140 |
Why?
|
| Enzyme Inhibitors | 1 | 2018 | 53 | 0.140 |
Why?
|
| Glucose | 1 | 2018 | 50 | 0.140 |
Why?
|
| MCF-7 Cells | 1 | 2026 | 15 | 0.060 |
Why?
|
| Mice, SCID | 1 | 2026 | 16 | 0.060 |
Why?
|
| Cell Movement | 1 | 2026 | 38 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2026 | 88 | 0.060 |
Why?
|
| Female | 2 | 2026 | 4060 | 0.050 |
Why?
|
| Models, Molecular | 1 | 2018 | 6 | 0.040 |
Why?
|
| Acetylation | 1 | 2018 | 10 | 0.040 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2018 | 10 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2018 | 45 | 0.040 |
Why?
|
| Hyperglycemia | 1 | 2018 | 27 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2018 | 73 | 0.040 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 29 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2018 | 56 | 0.030 |
Why?
|
| Disease Progression | 1 | 2018 | 170 | 0.030 |
Why?
|